LAG-3: from molecular functions to clinical applications

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune responses are tightly regulated by checkpoints to prevent autoimmunity.
• Inhibitory coreceptors like PD-1 and CTLA-4 are critical for immune regulation.
• Current immunotherapies targeting PD-1 and CTLA-4 have limitations in response rates and toxicity.

Purpose of the Study:

• To review the current understanding of Lymphocyte Activation Gene-3 (LAG-3).
• To highlight LAG-3 as a promising next-generation target for cancer immunotherapy.
• To discuss the discovery, function, and clinical applications of LAG-3.

Main Methods:

• Literature review of scientific publications on LAG-3.
• Analysis of existing data on immune coreceptors and their roles.
• Summary of ongoing clinical trials for LAG-3-targeted therapies.

Main Results:

• LAG-3 is an inhibitory coreceptor regulating T cell activation.
• LAG-3 plays significant roles in autoimmunity, tumor immunity, and anti-infection immunity.
• Multiple clinical trials are investigating LAG-3-targeted therapies for cancer.

Conclusions:

• LAG-3 represents a key target for next-generation cancer immunotherapies.
• Targeting LAG-3 holds potential for improved efficacy and reduced toxicity compared to current treatments.
• Further research and clinical evaluation of LAG-3 inhibitors are crucial for advancing cancer treatment.